106 related articles for article (PubMed ID: 26840263)
21. Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment.
Holton AB; Sinatra FL; Kreahling J; Conway AJ; Landis DA; Altiok S
PLoS One; 2017; 12(1):e0169797. PubMed ID: 28085924
[TBL] [Abstract][Full Text] [Related]
22. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
Li J; Viallet J; Haura EB
Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
[TBL] [Abstract][Full Text] [Related]
23. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors.
Li G; Tian L; Hou JM; Ding ZY; He QM; Feng P; Wen YJ; Xiao F; Yao B; Zhang R; Peng F; Jiang Y; Luo F; Zhao X; Zhang L; Zhou Q; Wei YQ
Clin Cancer Res; 2005 Jun; 11(11):4217-24. PubMed ID: 15930360
[TBL] [Abstract][Full Text] [Related]
24. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS
Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838
[TBL] [Abstract][Full Text] [Related]
25. Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked "nanosponge" network for lung cancer chemotherapy.
Hariri G; Edwards AD; Merrill TB; Greenbaum JM; van der Ende AE; Harth E
Mol Pharm; 2014 Jan; 11(1):265-75. PubMed ID: 24215299
[TBL] [Abstract][Full Text] [Related]
26. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
27. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
28. A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice.
Liu XJ; Zheng YB; Li Y; Wu SY; Zhen YS
PLoS One; 2014; 9(12):e115790. PubMed ID: 25531414
[TBL] [Abstract][Full Text] [Related]
29. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
Xu C; Langenheim JF; Chen WY
Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
[TBL] [Abstract][Full Text] [Related]
30. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.
Mediavilla-Varela M; Boateng K; Noyes D; Antonia SJ
BMC Cancer; 2016 Mar; 16():176. PubMed ID: 26935219
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment with the γ-secretase inhibitor DAPT sensitizes drug-resistant ovarian cancer cells to cisplatin by downregulation of Notch signaling.
Wang M; Ma X; Wang J; Wang L; Wang Y
Int J Oncol; 2014 Apr; 44(4):1401-9. PubMed ID: 24535252
[TBL] [Abstract][Full Text] [Related]
32. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
33. Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice.
Wang T; Chu Z; Lin H; Jiang J; Zhou X; Liang X
Mol Biol Rep; 2014 Jun; 41(6):4069-76. PubMed ID: 24615503
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
35. Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer.
Li D; Zhang Y; Xie Y; Xiang J; Zhu Y; Yang J
Cancer Gene Ther; 2013 Apr; 20(4):251-9. PubMed ID: 23470565
[TBL] [Abstract][Full Text] [Related]
36. N-(3-oxo-acyl) homoserine lactone inhibits tumor growth independent of Bcl-2 proteins.
Zhao G; Neely AM; Schwarzer C; Lu H; Whitt AG; Stivers NS; Burlison JA; White C; Machen TE; Li C
Oncotarget; 2016 Feb; 7(5):5924-42. PubMed ID: 26758417
[TBL] [Abstract][Full Text] [Related]
37. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
[TBL] [Abstract][Full Text] [Related]
39. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
40. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
